Atar D - Search Results

1

Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.

Serebruany VL, Malinin AI, Sane DC, Jilma B, Takserman A, Atar D, Hennekens CH. Serebruany VL, et al. Among authors: atar d. Eur J Pharmacol. 2004 Sep 24;499(3):315-24. doi: 10.1016/j.ejphar.2004.07.114. Eur J Pharmacol. 2004. PMID: 15381054 Clinical Trial.

2

Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease.

Malinin AI, Atar D, Callahan KP, McKenzie ME, Serebruany VL. Malinin AI, et al. Among authors: atar d. Eur J Pharmacol. 2003 Feb 21;462(1-3):139-43. doi: 10.1016/s0014-2999(02)02956-4. Eur J Pharmacol. 2003. PMID: 12591106 Clinical Trial.

3

Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.

Serebruany VL, Malinin AI, Oshrine BR, Sane DC, Takserman A, Atar D, Hennekens CH. Serebruany VL, et al. Among authors: atar d. Thromb Res. 2004;113(3-4):197-204. doi: 10.1016/j.thromres.2004.03.002. Thromb Res. 2004. PMID: 15140583

4

Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness.

Serebruany V, Malinin A, Ziai W, Atar D, Pokov A, Jilma B, Hanley D. Serebruany V, et al. Among authors: atar d. Cerebrovasc Dis. 2006;21(1-2):98-105. doi: 10.1159/000090207. Epub 2005 Dec 9. Cerebrovasc Dis. 2006. PMID: 16340184

5

Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.

Serebruany VL, Malinin AI, Atar D. Serebruany VL, et al. Among authors: atar d. Cardiology. 2007;107(4):307-12. doi: 10.1159/000099067. Epub 2007 Jan 30. Cardiology. 2007. PMID: 17264511

6

Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease.

Serebruany VL, Malinin AI, Atar D, Hanley DF. Serebruany VL, et al. Among authors: atar d. Am Heart J. 2007 Mar;153(3):371-7. doi: 10.1016/j.ahj.2006.12.006. Am Heart J. 2007. PMID: 17307414

7

Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease.

Serebruany VL, Malinin A, Ong S, Atar D. Serebruany VL, et al. Among authors: atar d. J Thromb Thrombolysis. 2008 Apr;25(2):207-13. doi: 10.1007/s11239-007-0047-3. Epub 2007 May 26. J Thromb Thrombolysis. 2008. PMID: 17530178

8

Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients.

Serebruany VL, Malinin AI, Ferguson JJ, Vahabi J, Atar D, Hennekens CH. Serebruany VL, et al. Among authors: atar d. Fundam Clin Pharmacol. 2008 Jun;22(3):315-21. doi: 10.1111/j.1472-8206.2008.00582.x. Fundam Clin Pharmacol. 2008. PMID: 18485150

9

The PLATO trial: do you believe in magic?

Serebruany VL, Atar D. Serebruany VL, et al. Among authors: atar d. Eur Heart J. 2010 Apr;31(7):764-7. doi: 10.1093/eurheartj/ehp545. Epub 2009 Dec 10. Eur Heart J. 2010. PMID: 20007979

10

Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin.

Serebruany VL, Glassman AH, Malinin AI, Atar D, Sane DC, Oshrine BR, Ferguson JJ, O'Connor CM. Serebruany VL, et al. Among authors: atar d. Eur J Heart Fail. 2003 Aug;5(4):517-21. doi: 10.1016/s1388-9842(03)00005-9. Eur J Heart Fail. 2003. PMID: 12921813 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

569 results

Search Page

Filters